174 related articles for article (PubMed ID: 12081158)
1. Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study.
Sharquie KE; Najim RA; Abu-Raghif AR
J Dermatol; 2002 May; 29(5):267-79. PubMed ID: 12081158
[TBL] [Abstract][Full Text] [Related]
2. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
3. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
4. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
Melikoglu M; Fresko I; Mat C; Ozyazgan Y; Gogus F; Yurdakul S; Hamuryudan V; Yazici H
J Rheumatol; 2005 Jan; 32(1):98-105. PubMed ID: 15630733
[TBL] [Abstract][Full Text] [Related]
5. Oral zinc sulfate in the treatment of Behcet's disease: a double blind cross-over study.
Sharquie KE; Najim RA; Al-Dori WS; Al-Hayani RK
J Dermatol; 2006 Aug; 33(8):541-6. PubMed ID: 16923135
[TBL] [Abstract][Full Text] [Related]
6. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
[TBL] [Abstract][Full Text] [Related]
7. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial.
Davatchi F; Sadeghi Abdollahi B; Tehrani Banihashemi A; Shahram F; Nadji A; Shams H; Chams-Davatchi C
Mod Rheumatol; 2009; 19(5):542-9. PubMed ID: 19597921
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study.
Matsuda T; Ohno S; Hirohata S; Miyanaga Y; Ujihara H; Inaba G; Nakamura S; Tanaka S; Kogure M; Mizushima Y
Drugs R D; 2003; 4(1):19-28. PubMed ID: 12568631
[TBL] [Abstract][Full Text] [Related]
9. Behçet's syndrome with pyoderma-gangrenosum-like lesions treated successfully with dapsone monotherapy.
Joshi A; Mamta
J Dermatol; 2004 Oct; 31(10):806-10. PubMed ID: 15672708
[TBL] [Abstract][Full Text] [Related]
10. Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement.
Mangelsdorf HC; White WL; Jorizzo JL
J Am Acad Dermatol; 1996 May; 34(5 Pt 1):745-50. PubMed ID: 8632067
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
Werth VP; Fivenson D; Pandya AG; Chen D; Rico MJ; Albrecht J; Jacobus D
Arch Dermatol; 2008 Jan; 144(1):25-32. PubMed ID: 18209165
[TBL] [Abstract][Full Text] [Related]
12. Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome.
Saini A; Ferguson C; Salkey K
J Drugs Dermatol; 2018 Dec; 17(12):1328-1329. PubMed ID: 30586267
[TBL] [Abstract][Full Text] [Related]
13. Behçet's disease and complex aphthosis.
Ghate JV; Jorizzo JL
J Am Acad Dermatol; 1999 Jan; 40(1):1-18; quiz 19-20. PubMed ID: 9922007
[TBL] [Abstract][Full Text] [Related]
14. A double-blind trial of colchicine in Behçet's syndrome.
Yurdakul S; Mat C; Tüzün Y; Ozyazgan Y; Hamuryudan V; Uysal O; Senocak M; Yazici H
Arthritis Rheum; 2001 Nov; 44(11):2686-92. PubMed ID: 11710724
[TBL] [Abstract][Full Text] [Related]
15. Adamantiades-Behçet Disease at the Beginning of the Silk Route: North-East Italian Experience.
Bergamo S; di Meo N; Stinco G; Bonin S; Trevisini S; Trevisan G
Acta Dermatovenerol Croat; 2017 Dec; 25(4):295-297. PubMed ID: 30064603
[TBL] [Abstract][Full Text] [Related]
16. Pathergy reaction in Behçet's disease: lack of correlation with mucocutaneous manifestations and systemic disease expression.
Krause I; Molad Y; Mitrani M; Weinberger A
Clin Exp Rheumatol; 2000; 18(1):71-4. PubMed ID: 10728447
[TBL] [Abstract][Full Text] [Related]
17. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Hotline. Oral allicin in the treatment of Behcet's disease through attenuating oxidative stress: A pilot study in 20 patients with mucocutaneous lesions.
Zhong J; Xian D; Xiong X; Liu J
Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27723197
[TBL] [Abstract][Full Text] [Related]
19. A double-blind trial of depot corticosteroids in Behçet's syndrome.
Mat C; Yurdakul S; Uysal S; Gogus F; Ozyazgan Y; Uysal O; Fresko I; Yazici H
Rheumatology (Oxford); 2006 Mar; 45(3):348-52. PubMed ID: 16263779
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of patients with Behçet's disease and epididymitis.
Cho YH; Jung J; Lee KH; Bang D; Lee ES; Lee S
J Urol; 2003 Oct; 170(4 Pt 1):1231-3. PubMed ID: 14501731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
